Prevent-SVD
Research type
Research Study
Full title
Preventing cognitive decline and dementia from cerebral small vessel disease
IRAS ID
181062
Contact name
Joanna Wardlaw
Contact email
Eudract number
2015-001953-33
ISRCTN Number
ISRCTN12580546
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 11 months, 30 days
Research summary
Why: About 35,000 people each year in the UK have a type of stroke, called ‘lacunar’ or ‘small vessel’ stroke, which is different to other common types of stroke and for
which there is no proven treatment. Small vessel stroke is caused by damage to the lining of the tiny blood vessels in the brain that stops the vessels functioning normally and damages the brain. This also causes up to 40% of all dementias.What: Two drugs, commonly used in other vessel diseases, may help prevent worsening of small vessel brain damage. One has not yet been tested specifically in lacunar stroke in the UK (Cilostazol) although it has been tested in Japan, and not on dementia; the other is widely used in heart disease but not stroke (isosorbide mononitrate).
Who: 60 patients with mild ischaemic stroke symptoms and signs, compatible with lacunar stroke, who are aged over 35 years, independent in activities of daily living and able to give consent themselves, in whom brain imaging has confirmed the lacunar stroke or excluded other causes of symptoms.
Where: The trial will be conducted at two UK regional expert stroke centres, Edinburgh and Nottingham.
How: This will be a short clinical trial to find out about how the patients feel taking the drugs, to test if they improve blood vessel function using some detailed scanning and blood vessel measurements, and find out if both drugs might be better than just one, before going on to a large clinical trial to find out if these drugs prevent worsening of small vessel disease.
REC name
Scotland A: Adults with Incapacity only
REC reference
15/SS/0154
Date of REC Opinion
1 Oct 2015
REC opinion
Favourable Opinion